

Faculty

Sandra Amor	Amsterdam
Antonio Bertolotto	Orbassano
Massimiliano Calabrese	Verona
Marco Castellaro	Verona
Francesco Crescenzo	Verona
Nicola De Stefano	Siena
Massimiliano Di Filippo	Perugia
Christian Enzinger	Graz
Massimo Filippi	Milano
Alberto Gajofatto	Verona
Simon Hametner	Wien
Owain Howell	Swansea
Matilde Inglese	Genova
Roberta Magliozzi	Verona
Damiano Marastoni	Verona
Roland Martin	Zurich
Salvatore Monaco	Verona
Richard Nicholas	London
Marco Pitteri	Verona
Francesca Benedetta Pizzini	Verona
Richard Reynolds	London
Mara Rocca	Milano
Antonio Scalfari	London
Claudio Solaro	Moncrivello
Christine Stadelmann-Nessler	Göttingen
Marco Vercellino	Torino
Luisa Maria Villar	Madrid

Scientific Direction

Massimiliano Calabrese
Roberta Magliozzi

Scientific Secretariat

Damiano Marastoni
Francesco Crescenzo
Francesca Benedetta Pizzini

100 Addressees

Medical Doctors specializing in
*neurology, neurosurgery, general medicine, radiology,
geriatrics, internal medicine, psychiatry, physical medicine
e rehabilitation.*

Pharmacists, Speech Therapists, Nurses,
Physiotherapists, Rehabilitation therapists,
Psychologists-Psychotherapists, Radiological
technicians, Neurophysiopathology technicians.

Under the patronage of



UNIVERSITÀ
di VERONA



REGIONE DEL VENETO

Sin
SOCIETÀ ITALIANA DI NEUROLOGIA

ASSOCIAZIONE
ITALIANA
NEUROIMMUNOLOGIA

With the support of

Biogen

NOVARTIS
caring and curing

MERCK

Roche

SANOFI

Segreteria
Organizzativa



Via Vittorio Veneto 11
35043 Monselice (PD)

tel. 0429 767 381
cell. 392 697 9059
info@eolocongressi.it



**Doppia modalità
di partecipazione online/onsite**




ISCRIZIONE GRATUITA ONLINE
su www.eolocongressi.it
indicando la propria preferenza

The silent activity of MULTIPLE SCLEROSIS molecular and imaging biomarkers

1st 2nd
OCTOBER
2020

Palace Hotel Desenzano
Viale Francesco Agello 114/A
Desenzano del Garda



The silent activity of
**MULTIPLE
SCLEROSIS**
molecular and imaging
biomarkers

The concept of “silent” disease activity as a hallmark of the disease even in the earliest phase and during the disease-modifying treatment, is emerging in the last few years. It describes those patients that, even in the absence of classical clinical/radiological events, have an insidious disease activity which is unnoticed by the patient or physician in the early phase of the disease, whereas it becomes clinically relevant later on disease course. This could be mainly characterized by neurodegenerative mechanisms rather than inflammatory disease activity and its measure is fairly beyond the sensitivity of the conventional MRI. One of the expressions of such silent activity may be a surface-in gradient of cortical, thalamic and spinal cord grey matter damage, which is a primary key component of the demyelination and neurodegeneration processes and provides the best clinical correlate in terms of long term disability accumulation. A second emerging relevant sign of silent activity is represented by the chronic active lesions which have been neuropathologically and radiologically well described and which have been proposed as one of the major determinants of disability progression.

According to this evidence, the unique use of No Evidence of Disease Activity (NEDA) status (no relapses, no new T2 and/or Gd-enhancing lesions, no EDSS change) is not completely appropriate to identify patients at high risk of a severe clinical outcome. The main goal of this symposium will be to better elucidate the most relevant molecular and radiological biomarkers of silent disease activity with special focus on Neuropathological, Imaging and CSF data.

1st

OCTOBER

8.30-17.30

8.30

Registration of participants

9.00

Welcome and Introduction
to the Meeting

Young Session 1

Chairs: F. Crescenzo, A. Gajofatto
and M. Pitteri

11.00 - 11.30

Coffee break

Young Session 2

Chairs: D. Marastoni and M. Castellaro

12.15 - 13.30

Light Lunch

Session 1

Chairs: M. Calabrese and R. Magliozzi

13.30 **Key Lecture. The Silent Disease activity
from the neuropathological point of view**
Christine Stadelmann-Nessler, Gottingen

14.00 **Key Lecture. B vs T cell in MS**
R. Martin, Zurich

14.30 **Cortical pathology in MS**
R. Reynolds, London

14.50 **Cortical demyelination in MS from the
imaging point of view**
M. Calabrese, Verona

15.10 **Cortical and deep GM atrophy**
N. De Stefano, Siena

15.30 **Discussion**

16.00 Coffee Break

Session 2

Chairs: M. Inglese and S. Monaco

16.40 **Iron related changes in MS:
from neuropathology to MRI**
S. Hametner, Wien

17.00 **Iron and MS from the imaging
point of view**
Chris Enzinger, Graz

17.20 **Discussion**

17.30 **Key Lecture. Imaging Biomarkers disease
activity and progression. An overview**
M. Filippi, Milan

2nd

OCTOBER

9.00-13.00

Session 3

Chairs: M. Di Filippo and M. Vercellino

9.00 **Meningeal inflammation in MS**
O. Howell, Swansea

9.20 **GM damage and disability**
A. Scalfari, London

9.40 **Microglial related disease activity**
S. Amor, Amsterdam

10.00 **Intrathecal inflammatory profile predicts
disease course in Multiple Sclerosis**
R. Magliozzi, Verona

10.20 **Discussion**

10.40 Coffee Break

Session 4

Chairs: C. Solaro and A. Bertolotto

11.20 **The role of Spinal cord in the disability
progression**
M. Rocca, Milan

11.40 **Brain aging in MS**
R. Nicholas, London

12.00 **Can biomarkers reflect silent
disease activity**
LM. Villar, Madrid

12.20 **Discussion**

12.40 **Closing remarks and proposal of a review**
Discussants: Massimiliano Calabrese, Roberta
Magliozzi, Mara Rocca, Antonio Scalfari,
Massimiliano Di Filippo, Antonio Bertolotto,
Claudio Solaro

13.00 **ECM Questionnaire**